Company: LIMN
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001104659-25-010605
Chunk: 845

Company: Liminatus Pharma, Inc.
Filing Date: 2025-02-07
Form: 424B3
Chunk 845
---
, registration, transfer, exchange, redemption and exercise of up to 6,900,000 warrants (the “ Public Warrants ”) underlying units issued in the Company’s initial public offering (the “ IPO ”), up to 5,013,333 warrants (the “ Private Placement Warrants ”) issued in a private placement consummated simultaneously with the IPO (the “ Private Placement ”), up to 1,000,000 Working Capital Warrants and any additional Post IPO Warrants;

WHEREAS, the IPO and the Private Placement were consummated on March 9, 2021;

WHEREAS, the Company has entered into a Business Combination Agreement (as amended, supplemented or otherwise modified from time to time, the “ Combination Agreement ”), which provides for a Business Combination between the Company and Liminatus Pharma, LLC, a Delaware limited liability company (“ Liminatus ”);

WHEREAS, pursuant to the Combination Agreement, (i) Liminatus Pharma Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of ParentCo, will merge with and into Liminatus (the “ Liminatus Merger ”), with Liminatus surviving the Liminatus Merger as a direct wholly-owned subsidiary of ParentCo, and (ii) simultaneously with the Liminatus Merger, SPAC Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of ParentCo, will merge with and into the Company (the “ SPAC Merger ” and, together with the Liminatus Merger, the “ Mergers ”), with the Company surviving the SPAC Merger as a direct wholly-owned subsidiary of ParentCo; and as a result of the Business Combination, holders of shares of Class A common stock of the Company and units of Liminatus will become holders of shares of common stock, par value $0.0001 per share, of ParentCo (“ ParentCo Common Stock ”);

WHEREAS, upon consummation of the Business Combination, as provided in Section 4.4 of the Warrant Agreement, the Warrants will no longer be exercisable for Common Stock of the Company but instead will be exercisable for ParentCo Common Stock; and

WHEREAS, in connection with the Business Combination, ParentCo wishes to confirm the assumption of the Company’s rights, duties, covenants and other obligations (the “ Obligations ”) under the Warrant Agreement;

NOW, THEREFORE, for good and valuable consideration, the receipt and adequacy of which are